LC-Plasma^™ News

Kyowa Hakko’s IMMUSE™, a research-backed postbiotic, provides immune support for travelers in this new innovative formula, “Well Traveled Immune Activator." Read More ›

Kyowa Hakko’s IMMUSE®, a clinically researched unique postbiotic, provides immune support in Lactoflor® Immuno 200 . Read More ›

After a resoundingly successful limited-time offering, Glaxon™ has now added Kyowa Hakko’s IMMUSE™ to all SuperGreens Immune formulas. Read More ›

With an impressive background in mining the microbiome for novel therapies, Prof. Hill helped with the definition of a postbiotic as a part of ISAPP. Read More ›

With a special interest in immune system dysfunction, including autoimmunity, allergy, and the stress-immune connection, Dr. Moday puts IMMUSE™, an award-winning postbiotic, at the forefront of ingredients to look out for in nutritional supplements. Read More ›

New consumer surveys reveal supplement users prefer branded ingredients 2x over generic ingredients when making purchasing decisions. Read More ›

Highlighted at the Annual Supply Side West Conference, the Function of Kyowa Hakko’s Novel Postbiotic was recognized as a leader for Immune Health. Read More ›

Kirin Holdings Company, Limited's (Kirin Holdings) iMUSE brand (IMMUSE in some markets), won the 2021 Product of the Year Award in the Immune Support category of the Nutralngredients-Asia Awards, held by William Reed Business Media (WRBM), a leading publisher of digital newsletters, publications and data sources for the food, beverage and nutrition industries worldwide. Read More ›

The solution offers superior ease of formulation, potential application versatility, and more comprehensive immune support compared to probiotics and other immune health ingredients. Read More ›

Kirin Holdings Company, Limited (Kirin Holdings) announces that it will expand manufacturing equipment at the iMUSE Health Science Factory (located in Saitama Prefecture, just north of Tokyo) - a manufacturing center for lactic acid bacteria raw material - in order to meet the increasing demand for Kirin's proprietary Lactococcus lactis strain Plasma (L. lactis strain Plasma), the functional ingredient in the popular iMUSE brand of immune maintenance products. The new manufacturing equipment is scheduled to begin operating in 2023, and will double the annual production capacity of L. lactis strain Plasma to approximately 28 tons in 2023. Read More ›